🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchSurvodutide (GCG/GLP-1) — MASH and obesity trial results Page 3

Survodutide (GCG/GLP-1) — MASH and obesity trial results

MASHdoc_SA Sat, Jun 6, 2026 at 8:40 PM 16 replies 467 viewsPage 3 of 4
pete_nash
Member
312
1,345
Aug 2024
Nashville, TN
Jun 7, 2026 at 6:10 PM#11
Dr.SurgeonPGH said:
The liver data is among the strongest non-weight findings in the class.

Bookmarking. The distinction being drawn above is the one nobody else makes.

33 8Admin, Dr.Martinez, mike_mod and 30 others
Reply Quote Save Share Report
GenomicsKate
Member
345
1,890
Oct 2024
Cambridge, MA
Jun 7, 2026 at 9:01 PM#12

From the other side of the consultation, briefly. The version of this that has an answer is narrower than the version being asked. Narrow it and it becomes tractable; leave it broad and the thread will produce nine confident and incompatible replies.

Correct me if the detail matters more than I have assumed.

32 7KristenIndy, MarkLI_maint, Dr.PeteFamMed and 29 others
Reply Quote Save Share Report
Dr.AddMedPHL
Senior Member
1,234
6,234
Mar 2024
Philadelphia, PA
Jun 7, 2026 at 11:52 PM#13
BariatricNurseD said:
It is worth asking what the claim would look like if it were false.

Pushing back on BariatricNurseD here. Pushing back on the anecdote-stacking. Twenty people reporting the same thing is twenty samples from the same self-selected pool, not twenty independent confirmations.

31 6mike.trainer_LA, sarah_nash92, FitDadDave and 28 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
PharmacoVig_BOS
Senior Member
1,567
8,901
Feb 2024
Boston, MA
Jun 8, 2026 at 2:44 AM#14

Adding the numbers, since they settle part of this. If you are going to change something, change one thing and give it long enough to express itself. Four weeks is the usual minimum for anything pharmacological on this board, and two weeks of data has told you almost nothing.

If somebody has the primary source to hand I would rather cite it than paraphrase it.

30 5kate.chem, DataDave, Dr.GutHealth and 27 others
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
Jun 8, 2026 at 5:35 AM#15

Moderator note: leaving this open. It is being argued well and the disagreement is the useful part. Thread quality here is what the rules are for. Keep it up.

Last edited: Jun 8, 2026 at 7:35 AM
29 4PurityPaulOR, MaxMetOK, MounjBrad and 26 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register